Latest Pharma Insights
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time
Restructuring Edition: Replimune said RP1 development is not viable without accelerated approval, so it is cutting jobs. Cyclerion Therapeutics, Kezar Life Sciences and Assertio announced reverse mergers or other acquisitions, while IO Biotech, Iterum and Lipella filed for bankruptcy.
Scrip - April 10, 2026
Restructuring Edition: Replimune said RP1 development is not viable without accelerated approval, so it is cutting jobs. Cyclerion Therapeutics, Kezar Life Sciences and Assertio announced reverse mergers or other acquisitions, while IO Biotech, Iterum and Lipella filed for bankruptcy.
Scrip - April 10, 2026
UMSOM Researcher To Drive Innovation By Making New Cervix ‘Organ-On-A-Chip’ Widely Accessible
Researchers at the University of Maryland School of Medicine developed a cervical organ-on-a-chip model that will be accessible to all researchers. Lead researcher Jacques Ravel believes that this model will drive innovation and new treatments for STIs in women.
Medtech Insight - April 10, 2026
Researchers at the University of Maryland School of Medicine developed a cervical organ-on-a-chip model that will be accessible to all researchers. Lead researcher Jacques Ravel believes that this model will drive innovation and new treatments for STIs in women.
Medtech Insight - April 10, 2026
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1
Evaluate and Scrip tracked six IPOs by drug developers on Western exchanges in the first quarter, a total not seen since Q1 of 2025. The $1.81bn raised was the highest since Q4 of 2021.
Scrip - April 10, 2026
Evaluate and Scrip tracked six IPOs by drug developers on Western exchanges in the first quarter, a total not seen since Q1 of 2025. The $1.81bn raised was the highest since Q4 of 2021.
Scrip - April 10, 2026
Global Medtech Guidance Tracker: March 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 80 documents have been posted on the tracker since its last update.
Medtech Insight - April 10, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 80 documents have been posted on the tracker since its last update.
Medtech Insight - April 10, 2026
Medline Recalls Millions Of Angiographic Syringes After FDA Warning Letter
Medline is recalling millions of Namic angiographic control syringes after reports of serious injury. The recall follows a warning letter the company received from the FDA after an inspection of its New York facility.
Medtech Insight - April 10, 2026
Medline is recalling millions of Namic angiographic control syringes after reports of serious injury. The recall follows a warning letter the company received from the FDA after an inspection of its New York facility.
Medtech Insight - April 10, 2026
Boehringer Hands CT-155 Commercial Rights To Click Therapeutics In $50M Deal Restructure
A five-year partnership for a schizophrenia digital therapeutic has been restructured in a way that tells a broader story: Now Click Therapeutics will take full responsibility for CT-155’s commercialization, backed by a $50m Series D investment and continued clinical collaboration.
Medtech Insight - April 10, 2026
A five-year partnership for a schizophrenia digital therapeutic has been restructured in a way that tells a broader story: Now Click Therapeutics will take full responsibility for CT-155’s commercialization, backed by a $50m Series D investment and continued clinical collaboration.
Medtech Insight - April 10, 2026
Organon Rumors Persist Despite Sun’s Fresh Denial
Sun Pharma reiterates that Organon deal reports are “speculative” even as detailed claims of a $12bn bid process unsettle investors, highlighting the potential for a transformational but highly leveraged and strategically complex acquisition.
Generics Bulletin - April 10, 2026
Sun Pharma reiterates that Organon deal reports are “speculative” even as detailed claims of a $12bn bid process unsettle investors, highlighting the potential for a transformational but highly leveraged and strategically complex acquisition.
Generics Bulletin - April 10, 2026
Pipeline Watch: Three Approvals And Thirteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 10, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 10, 2026
Outlook Goes After FDA With Formal Dispute Resolution Request
Outlook will be meeting again with the FDA to discuss the approval of its ophthalmic formulation of bevacizumab. However, this time, Outlook will go through a different procedural pathway.
Generics Bulletin - April 10, 2026
Outlook will be meeting again with the FDA to discuss the approval of its ophthalmic formulation of bevacizumab. However, this time, Outlook will go through a different procedural pathway.
Generics Bulletin - April 10, 2026
‘The Number One Priority Is Sustainable Access’ – AAM Chair Hoffman On Stabilizing The US Industry
Fresh from taking over the role of AAM chair, Lupin’s Bob Hoffman talks to Generics Bulletin about how the “squeezed” US off-patent industry is having to work hard just to remain sustainable – and the messages that US policymakers need to hear.
Generics Bulletin - April 10, 2026
Fresh from taking over the role of AAM chair, Lupin’s Bob Hoffman talks to Generics Bulletin about how the “squeezed” US off-patent industry is having to work hard just to remain sustainable – and the messages that US policymakers need to hear.
Generics Bulletin - April 10, 2026
GTCR Takeover Fuels Zentiva Expansion Across European Markets
GTCR has closed its acquisition of Zentiva, backing further expansion in generics, biosimilars and consumer health as the European off-patent sector faces rising policy focus on supply security, affordability and sustainability.
Generics Bulletin - April 10, 2026
GTCR has closed its acquisition of Zentiva, backing further expansion in generics, biosimilars and consumer health as the European off-patent sector faces rising policy focus on supply security, affordability and sustainability.
Generics Bulletin - April 10, 2026
Top 12 Pharma Companies: Eli Lilly Shoots To The Top, Merck Tumbles
2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent.
Scrip - April 10, 2026
2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent.
Scrip - April 10, 2026
Iran War: India’s Supply Chain Shocks, Contract Stress And Spillover Risks
The Iran war has turned the region into a powder keg and pharma in India is tackling systemic supply chain shocks with some solvent/chemical suppliers declaring force majeure, and also related contract stress.
Scrip - April 10, 2026
The Iran war has turned the region into a powder keg and pharma in India is tackling systemic supply chain shocks with some solvent/chemical suppliers declaring force majeure, and also related contract stress.
Scrip - April 10, 2026
MacroGenics Avoids Worst-Case Scenario For Lorigerlimab As US FDA Lifts Trial Hold
The next phase of the LINNET study would be crucial in establishing lorigerlimab’s role within the company’ broader oncology pipeline.
Scrip - April 10, 2026
The next phase of the LINNET study would be crucial in establishing lorigerlimab’s role within the company’ broader oncology pipeline.
Scrip - April 10, 2026
Sumitomo Pharma To Fortify R&D, Pay Off Debt Through $730m Stock Offering
Japanese firm plans to allocate nearly half of new funds to paying back loans on past "vant" acquisitions, with remainder going mostly to support refocused R&D.
Scrip - April 10, 2026
Japanese firm plans to allocate nearly half of new funds to paying back loans on past "vant" acquisitions, with remainder going mostly to support refocused R&D.
Scrip - April 10, 2026
Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time
Restructuring Edition: Replimune said RP1 development is not viable without accelerated approval, so it is cutting jobs. Cyclerion Therapeutics, Kezar Life Sciences and Assertio announced reverse mergers or other acquisitions, while IO Biotech, Iterum and Lipella filed for bankruptcy.
Scrip - April 10, 2026
Restructuring Edition: Replimune said RP1 development is not viable without accelerated approval, so it is cutting jobs. Cyclerion Therapeutics, Kezar Life Sciences and Assertio announced reverse mergers or other acquisitions, while IO Biotech, Iterum and Lipella filed for bankruptcy.
Scrip - April 10, 2026
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1
Evaluate and Scrip tracked six IPOs by drug developers on Western exchanges in the first quarter, a total not seen since Q1 of 2025. The $1.81bn raised was the highest since Q4 of 2021.
Scrip - April 10, 2026
Evaluate and Scrip tracked six IPOs by drug developers on Western exchanges in the first quarter, a total not seen since Q1 of 2025. The $1.81bn raised was the highest since Q4 of 2021.
Scrip - April 10, 2026
Pipeline Watch: Three Approvals And Thirteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 10, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 10, 2026
Top 12 Pharma Companies: Eli Lilly Shoots To The Top, Merck Tumbles
2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent.
Scrip - April 10, 2026
2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent.
Scrip - April 10, 2026
Iran War: India’s Supply Chain Shocks, Contract Stress And Spillover Risks
The Iran war has turned the region into a powder keg and pharma in India is tackling systemic supply chain shocks with some solvent/chemical suppliers declaring force majeure, and also related contract stress.
Scrip - April 10, 2026
The Iran war has turned the region into a powder keg and pharma in India is tackling systemic supply chain shocks with some solvent/chemical suppliers declaring force majeure, and also related contract stress.
Scrip - April 10, 2026
MacroGenics Avoids Worst-Case Scenario For Lorigerlimab As US FDA Lifts Trial Hold
The next phase of the LINNET study would be crucial in establishing lorigerlimab’s role within the company’ broader oncology pipeline.
Scrip - April 10, 2026
The next phase of the LINNET study would be crucial in establishing lorigerlimab’s role within the company’ broader oncology pipeline.
Scrip - April 10, 2026
Sumitomo Pharma To Fortify R&D, Pay Off Debt Through $730m Stock Offering
Japanese firm plans to allocate nearly half of new funds to paying back loans on past "vant" acquisitions, with remainder going mostly to support refocused R&D.
Scrip - April 10, 2026
Japanese firm plans to allocate nearly half of new funds to paying back loans on past "vant" acquisitions, with remainder going mostly to support refocused R&D.
Scrip - April 10, 2026
UMSOM Researcher To Drive Innovation By Making New Cervix ‘Organ-On-A-Chip’ Widely Accessible
Researchers at the University of Maryland School of Medicine developed a cervical organ-on-a-chip model that will be accessible to all researchers. Lead researcher Jacques Ravel believes that this model will drive innovation and new treatments for STIs in women.
Medtech Insight - April 10, 2026
Researchers at the University of Maryland School of Medicine developed a cervical organ-on-a-chip model that will be accessible to all researchers. Lead researcher Jacques Ravel believes that this model will drive innovation and new treatments for STIs in women.
Medtech Insight - April 10, 2026
Global Medtech Guidance Tracker: March 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 80 documents have been posted on the tracker since its last update.
Medtech Insight - April 10, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 80 documents have been posted on the tracker since its last update.
Medtech Insight - April 10, 2026
Medline Recalls Millions Of Angiographic Syringes After FDA Warning Letter
Medline is recalling millions of Namic angiographic control syringes after reports of serious injury. The recall follows a warning letter the company received from the FDA after an inspection of its New York facility.
Medtech Insight - April 10, 2026
Medline is recalling millions of Namic angiographic control syringes after reports of serious injury. The recall follows a warning letter the company received from the FDA after an inspection of its New York facility.
Medtech Insight - April 10, 2026
Boehringer Hands CT-155 Commercial Rights To Click Therapeutics In $50M Deal Restructure
A five-year partnership for a schizophrenia digital therapeutic has been restructured in a way that tells a broader story: Now Click Therapeutics will take full responsibility for CT-155’s commercialization, backed by a $50m Series D investment and continued clinical collaboration.
Medtech Insight - April 10, 2026
A five-year partnership for a schizophrenia digital therapeutic has been restructured in a way that tells a broader story: Now Click Therapeutics will take full responsibility for CT-155’s commercialization, backed by a $50m Series D investment and continued clinical collaboration.
Medtech Insight - April 10, 2026
White House Requests FDA Food Programs Spending Boost But Lower Overall FY 2027 Budget
Request would set FDA’s next budget at $7.23bn after it received just short of $7bn for FY2026; includes $3.306bn in direct appropriations, $47.8m less than in the current budget, and increases total support from user fees by $280m to $3.92bn.
HBW Insight - April 9, 2026
Request would set FDA’s next budget at $7.23bn after it received just short of $7bn for FY2026; includes $3.306bn in direct appropriations, $47.8m less than in the current budget, and increases total support from user fees by $280m to $3.92bn.
HBW Insight - April 9, 2026
Children’s Beauty Boom Signals Caution for Brands In Europe
Beauty products sold in Europe face scrutiny over children’s growing use of skin care and cosmetics as regulators examine safety obligations under EU law and investigate marketing practices targeting minors.
HBW Insight - April 9, 2026
Beauty products sold in Europe face scrutiny over children’s growing use of skin care and cosmetics as regulators examine safety obligations under EU law and investigate marketing practices targeting minors.
HBW Insight - April 9, 2026
Opella Sees Role For Evidence?Based Self?Care In Early MASLD Care
New clinical evidence suggests evidence?based self?care can play a meaningful role in managing MASLD, a common fatty liver condition linked to obesity and diabetes, supporting lifestyle change and opening growth opportunities in an underdeveloped liver health category.
HBW Insight - April 9, 2026
New clinical evidence suggests evidence?based self?care can play a meaningful role in managing MASLD, a common fatty liver condition linked to obesity and diabetes, supporting lifestyle change and opening growth opportunities in an underdeveloped liver health category.
HBW Insight - April 9, 2026
People On The Move: Appointments At Barentz, iHerb, Lonza
A round up of the latest European health & wellness people moves: Barentz names first Human Nutrition EMEA VP; iHerb hires Europe general manager; Lonza adds experience to board.
HBW Insight - April 9, 2026
A round up of the latest European health & wellness people moves: Barentz names first Human Nutrition EMEA VP; iHerb hires Europe general manager; Lonza adds experience to board.
HBW Insight - April 9, 2026
Researchers Make Case To Expand Medication Abortion Access But Note OTC Approval Unlikely
Researchers from Advancing New Standards in Reproductive Health at University of California, San Francisco, say mifepristone/misoprostol medication abortion “likely meets” FDA criteria for OTC sales but acknowledge it’s unlikely they will become available nonprescription.
HBW Insight - April 9, 2026
Researchers from Advancing New Standards in Reproductive Health at University of California, San Francisco, say mifepristone/misoprostol medication abortion “likely meets” FDA criteria for OTC sales but acknowledge it’s unlikely they will become available nonprescription.
HBW Insight - April 9, 2026
Organon Rumors Persist Despite Sun’s Fresh Denial
Sun Pharma reiterates that Organon deal reports are “speculative” even as detailed claims of a $12bn bid process unsettle investors, highlighting the potential for a transformational but highly leveraged and strategically complex acquisition.
Generics Bulletin - April 10, 2026
Sun Pharma reiterates that Organon deal reports are “speculative” even as detailed claims of a $12bn bid process unsettle investors, highlighting the potential for a transformational but highly leveraged and strategically complex acquisition.
Generics Bulletin - April 10, 2026
Outlook Goes After FDA With Formal Dispute Resolution Request
Outlook will be meeting again with the FDA to discuss the approval of its ophthalmic formulation of bevacizumab. However, this time, Outlook will go through a different procedural pathway.
Generics Bulletin - April 10, 2026
Outlook will be meeting again with the FDA to discuss the approval of its ophthalmic formulation of bevacizumab. However, this time, Outlook will go through a different procedural pathway.
Generics Bulletin - April 10, 2026
‘The Number One Priority Is Sustainable Access’ – AAM Chair Hoffman On Stabilizing The US Industry
Fresh from taking over the role of AAM chair, Lupin’s Bob Hoffman talks to Generics Bulletin about how the “squeezed” US off-patent industry is having to work hard just to remain sustainable – and the messages that US policymakers need to hear.
Generics Bulletin - April 10, 2026
Fresh from taking over the role of AAM chair, Lupin’s Bob Hoffman talks to Generics Bulletin about how the “squeezed” US off-patent industry is having to work hard just to remain sustainable – and the messages that US policymakers need to hear.
Generics Bulletin - April 10, 2026
GTCR Takeover Fuels Zentiva Expansion Across European Markets
GTCR has closed its acquisition of Zentiva, backing further expansion in generics, biosimilars and consumer health as the European off-patent sector faces rising policy focus on supply security, affordability and sustainability.
Generics Bulletin - April 10, 2026
GTCR has closed its acquisition of Zentiva, backing further expansion in generics, biosimilars and consumer health as the European off-patent sector faces rising policy focus on supply security, affordability and sustainability.
Generics Bulletin - April 10, 2026
Deals Shaping The Industry, March 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026
Podcast: How Israel Is Positioning Itself As A Global Innovation Hub
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026